MedinCell develops long-acting injectable products for animal health. Their MedinGelâ¢ delivery platform enables partners to develop differentiated, controlled-release products using small molecules or peptides (NCEs or generic APIs). The system is based upon proprietary polymers that form a semi-solid depot within the body. Through biodegradation, a therapeutic dosage can be maintained for a few days, weeks, months, or even across an entire year. Since no API modifications are required, formulation development is very rapid. MedinGelâ¢ low cost-of-goods enables us to develop best-in-class products for partners in parasitology, pain, metabolic disorders, and other key animal health markets.
MedinCell USA's Chief Executive Officer Chris Hoover will be speaking at the event on the subject of lowering costs and increasing adherence with novel drug delivery systems. Hoover will address identifying cost savings of extended-release formulations and developing custom drug administration for targeted animal health markets.
Interested in meeting up with MedinCell representatives to discuss business opportunities in the animal health industry? Check out the World Animal Health Congress to find out more about your best networking opportunities with MedinCell and many others.